Valion Bio, Inc. (VBIO) News
Follow Valion Bio, Inc. (VBIO) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 18 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Valion Bio Evaluates Options After Unsolicited Acquisition Inquiries
Valion Bio received unsolicited acquisition inquiries for Velocity Bioworks and is evaluating strategic options, including a possible sale.
MNA | Oct 26, 2026, 12:03 PM UTC
L
Valion Bio, Inc. (VBIO) Advances Oral Mucosal Entolimod; Next Test Targets Systemic Exposure
Valion Bio, Inc. and SKL completed formulation of an oral mucosal Entolimod using BioViscid. Valion says a successful program could expand potential U.S. dose needs ~10—40x vs injectable; next study will test for measura
NEWS | Sep 30, 2026, 11:48 AM UTC
L
Valion Bio and Shear Kershman Laboratories Successfully Formulate Oral Mucosal Entolimod; Valion Sees Potential for Multi-Fold Expansion of Long-Term Opportunity
Needle-free program creates a potential second development pathway alongside Valion's injectable Entolimod programNext study will test whether the formulation delivers measurable amounts of Entolimod into the bloodstream
NEWS | Sep 30, 2026, 11:48 AM UTC
L
Weekly Recap: Nasdaq compliance regained and leadership, audit oversight changes
Valion Bio, Inc. (NASDAQ:VBIO) said Nasdaq closed its noncompliance case after VBIO kept its share price above $1.00, and announced leadership changes—Dean Zikria as interim CEO, Thomas Jensen as board chair and Jared Ma
NEWS | Sep 28, 2026, 11:07 AM UTC
L
Dean Zikria named Interim Chief Executive Officer at Valion Bio; Sheryle Bolton resigns from board
Valion Bio appointed Dean Zikria as Interim Chief Executive Officer, effective September 22, 2026, and disclosed the resignation of director Sheryle Bolton effective September 17, 2026.Original SEC Filing: Valion Bio, In
REGULATION | Sep 23, 2026, 12:04 PM UTC
L
Valion Bio, Inc. (VBIO) Names Interim CEO, Shifts Board Roles
Valion Bio, Inc. appointed director Dean Zikria as interim CEO and named Thomas Jensen Board Chair and Jared Malbin Audit Chair; Sheryle Bolton left the Board.Material DetailsContext by AI AnalystThis is an early-to-mid
NEWS | Sep 23, 2026, 12:01 PM UTC
L
Valion Appoints Life Sciences Veteran Dean Zikria as Interim CEO and Announces Board Leadership Transitions
Leadership changes strengthen alignment and execution as Company advances Entolimod and evaluates strategic, commercial and government opportunitiesSAN ANTONIO, TX / / September 23, 2026 / Valion Bio, Inc. NASDAQ:VBIO ("
NEWS | Sep 23, 2026, 12:01 PM UTC
L
VBIO - Valion Appoints Life Sciences Veteran Dean Zikria as Interim CEO and Announces Board Leadership Transitions
VBIO - Valion Appoints Life Sciences Veteran Dean Zikria as Interim CEO and Announces Board Leadership Transitions
NEWS | Sep 23, 2026, 12:00 PM UTC
L
VBIO - Valion Bio Regains Compliance with NASDAQ Minimum Bid Price Listing Rule
VBIO - Valion Bio Regains Compliance with NASDAQ Minimum Bid Price Listing Rule
NEWS | Sep 22, 2026, 12:00 PM UTC
L
VBIO - Valion Bio Announces Changes to Management and Board of Directors
VBIO - Valion Bio Announces Changes to Management and Board of Directors
EQUITY | Sep 01, 2026, 12:00 PM UTC
L
Valion Bio names CFO Lisa Wolf President and COO
Valion Bio said its current CFO, Lisa Wolf, was named President and COO with expanded executive and operational leadership. Jared Malbin and Thomas Jensen were appointed as directors.
EQUITY | Sep 01, 2026, 12:00 PM UTC
L
Valion Bio appoints two directors to board effective Aug. 27
Valion Bio appointed Jared Malbin and Thomas Jensen to its board of directors, effective August 27, 2026.
REGULATION | Sep 01, 2026, 10:15 AM UTC
M
Valion Bio raises $7.737 million via Series B/C preferred and warrants
Valion Bio entered a private placement letter agreement with 3i to issue Series B and Series C preferred shares with accompanying warrants for $7.737 million.
EQUITY | Sep 01, 2026, 10:15 AM UTC
L
Valion Bio announces reverse stock split
Valion Bio announced a reverse stock split.
EQUITY | Aug 27, 2026, 12:30 PM UTC
M
VBIO: Ukraine Health Ministry advances Entolimod review to technical assessment
Ukraine's Ministry of Health advances Entolimod review into a technical assessment phase, according to TradeXchange Newsdesk, with VBIO linked to the development.
REGULATION | Aug 13, 2026, 02:00 PM UTC
M
Valion Bio Announces US Govt Studies
Valion Bio announces US government-funded Entolimod studies
EQUITY | Aug 12, 2026, 01:31 PM UTC
H
VBIO: Pentagon Completes Protocol
Valion Bio announces the Pentagon's Armed Forces Radiobiology Research Institute and National Institute of Allergy and Infectious Diseases completed the design of a survival efficacy protocol to evaluate Entolimod for tr
EQUITY | Jun 25, 2026, 11:48 AM UTC
H
VBIO: AFRRI/NIAID Tests Entolimod
AFRRI/NIAID designs protocol to evaluate Valion Bio's Entolimod as treatment for GI-ARS
EQUITY | Jun 25, 2026, 11:47 AM UTC